BioIVT completed the acquisition of BeCytes Biotechnologies.

BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, completed the acquisition of BeCytes Biotechnologies, a biotechnology company. Financial terms were not disclosed. “At BeCytes, our vision has always been to accelerate preclinical research to improve patients’ lives by driving innovation and enabling scientific discovery. For years, we have viewed BioIVT as a benchmark of excellence in our industry, with the global reach and expertise to match. This partnership marks an exciting step forward in our shared mission - expanding our capabilities and strengthening our connection with the research community. We are proud to join forces with the world-class team at BioIVT,” Jordi Xapelli, BeCytes Biotechnologies CEO.